Therapeutic news in ALS

Philippe Corcia (1) , Stéphane Beltran (1) , Salah Eddine Bakkouche (1) , Philippe Couratier (2, 3)

1 SLA CHRU Tours - Centre de compétence de la Sclérose Latérale Amyotrophique [CHRU Tours]
2 NET - Neuroépidémiologie Tropicale
3 Service de Neurologie [CHU Limoges]

Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease characterized by death of motor neurons in the cortex and the spinal cord. This loss of motor neurons causes progressive weakness and amyotrophy. To date, the median duration of survival in patients with ALS, from first symptoms to death, is estimated to be 36 months. Currently the treatment is limited to two options: riluzole which prolongs survival for a few months and edaravone which is available in only a few countries and also has a small impact on disease progression. There is an urgent need for more effective drugs in this disease to significantly improve progression. Over the last 30 years, all trials have failed to find a curative drug for ALS. This is due, partially, to the heterogeneity of the clinical features and the pathophysiology of motor neuron death. We present in this review the various treatment options currently being developed for ALS, with an emphasis on the range of therapeutic approaches being explored, from old drugs tested in a new indication to innovative drugs obtained via biotechnology or gene therapy.

Mots clés: Amyotrophic Lateral Sclerosis; Therapeutic-clinical trials

Domaines: Santé publique et épidémiologie

Philippe Corcia, Stéphane Beltran, Salah Eddine Bakkouche, Philippe Couratier. Therapeutic news in ALS. Revue Neurologique, 2021, 177 (5), pp.544-549. ⟨10.1016/j.neurol.2020.12.003⟩. ⟨hal-03331917⟩